TELEFLEX INC 8-K

What Happened
Teleflex Incorporated filed an 8‑K on Feb. 26, 2026 announcing its financial results for the year ended Dec. 31, 2025 via a press release and slide presentation. The company disclosed and explained various non‑GAAP measures (adjusted revenue, adjusted constant‑currency growth, pro forma adjusted revenue, and adjusted diluted EPS) that exclude certain items—most notably a reserve increase related to an Italian National Healthcare System “payback” court ruling and other one‑time items. Teleflex also reported that on Feb. 23, 2026 its Board approved a multi‑year restructuring plan tied to the company’s Strategic Divestitures to realign organizational structure and supply chain; the plan is expected to be substantially completed by mid‑2028.

Key Details

• Restructuring estimates: $15M–$18M of restructuring charges (mostly employee termination costs) plus $16M–$19M of restructuring‑related charges, totaling $31M–$37M.
• Cash impact and timing: Most charges are expected to be cash outlays; $15M–$19M of the cash is expected to occur in 2026. Full plan implementation is expected to deliver $48M–$52M of annual pre‑tax savings.
• Non‑GAAP adjustments: Adjusted revenues exclude the increase in reserves for prior years tied to the Italian payback requirement (resulting from a recent court ruling). Pro forma adjusted revenues also exclude ≈$14M of products discontinued in 2025 and include six months of revenues from the Vascular Intervention business acquired from BIOTRONIK (for the six months ended June 29, 2025).
• Adjusted diluted EPS excludes items such as restructuring and optimization charges, impairments, acquisition/integration/divestiture costs, separation costs for the Strategic Divestitures, Italian payback impacts, amortization, ERP/IT transition costs, pension termination charges, EU MDR registration costs, and certain tax adjustments.

Why It Matters
Investors should note Teleflex’s presentation of non‑GAAP metrics is intended to isolate core operating trends by removing one‑time impacts (notably the Italian payback reserve and divestiture‑related items). The restructuring tied to the Strategic Divestitures carries a modest near‑term charge ($31M–$37M) but is projected to generate meaningful ongoing cost savings ($48M–$52M annually) once complete, with some savings beginning in 2026. The combination of one‑time charges, separation costs and the inclusion of acquired Vascular Intervention revenues affects period‑to‑period comparability of earnings and revenue growth; investors should review the GAAP results alongside the company’s reconciliations and the press release exhibits for full context.